01 July, 2016

Trans-Hit Bio Collaboration with Biokaizen on the Development of Blood-Based Diagnostics for Alzheimer’s Disease yields a Presentation at the Alzheimer’s Association International Conference

Montreal - Canada

The results of studies conducted by Biokaizen Lab, an emerging leader in personalized diagnostics that has been actively collaborating with Trans-Hit since 2013, will be presented at the 2016 Alzheimer’s Association International Conference on Wednesday, July 27, 2016.These studies aimed to develop a serum-based biomarker score for detecting molecular alterations of cognitive decline that occur throughout the continuum of Alzheimer’s disease pathophysiology especially for the early phases of cognitive decline. 


About Biokaizen Lab

BioKaizen Lab, located in Monthey, Switzerland, owns unmatched biomarker discovery methods based on a platform technology able to measure tens of thousands of biomolecules in a single drop of blood and their personalization according to genetic differences and a patient’s testing history. These methods of personalized diagnosis derived from the Biological Passport program solve today’s dilemma that exists between the necessity to diagnose a disease early and the concomitant risk of over-diagnosis and over-treatment. Relying on the longstanding experience in biotechnology and clinical laboratory services of its management team, BioKaizen aims to make predictive, personalized, preventive, participatory P4 medicine easily accessible to everyone.